HIGHLIGHTS
- who: OAT and colleagues from the Department of Medical Oncology, Erasmus MC Cancer Institute, CE Rotterdam, The Netherlands have published the paper: Pharmacodynamics of Sorafenib, in the Journal: (JOURNAL)
- what: This study was designed to determine bioequivalence with geometric mean Area under the curve from zero to twelve hours (AUC0-12 h ) as primary endpoint. As part of an ongoing project to develop translationally useful prevention strategies for sorafenib-induced HFSR, in the current study, the authors evaluated the pharmacokinetics (PK) and safety of sorafenib when concomitantly used with probenecid. The aim of this study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.